Trial · NCT05289492
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
NCT05289492, Phase 1, Terminated, iTeos Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma. Trials, record NCT05289492. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05289492
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- NCT number
- NCT05289492
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- iTeos Therapeutics
- Conditions
- Multiple Myeloma
- Interventions
- EOS884448, Iberdomide, Dexamethasone
- First posted
- 2022-03-21
- Last updated
- 2024-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with any adverse events (AEs) and serious adverse events (SAEs) | From first study treatment administration up to 120 days after the last dose | |
| Primary | Number of participants with dose limiting toxicity (DLT) | From first study treatment administration up to 120 days after the last dose | |
| Primary | Recommended Phase 2 dose (RP2D) of EOS884448 alone or in combinations with iberdomide with or without dexamethasone in participants with relapse/refractory multiple myeloma | up to 2 years | |
| Primary | Number of participants with overall response (partial or better) as determined by IMWG criteria | up to 2 years | |
| Secondary | Progression-free-survival (PFS) | Until disease progression or death - Approximately 24 months | |
| Secondary | Duration of Response (DOR) | Until disease progression or death - Approximately 24 months | |
| Secondary | Time to Response (TTR) | Approximately 48 weeks | |
| Secondary | Maximum concentration (Cmax) of EOS884448 at each dose level | Approximately 48 weeks | |
| Secondary | Percentage of participants with anti-drug antibodies to EOS884448 | Approximately 48 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05289492
GET https://conductscience.org/api/trials/v1/NCT05289492/registered